Becton, Dickinson and Company (NYSE:BDX) Price Target Cut to $150.00 by Analysts at The Goldman Sachs Group

Becton, Dickinson and Company (NYSE:BDX) had its price target dropped by analysts at The Goldman Sachs Group from $156.00 to $150.00 in a research note issued to investors on Wednesday,MarketScreener reports. The brokerage presently has a “neutral” rating on the medical instruments supplier’s stock. The Goldman Sachs Group’s price objective would indicate a potential upside of 2.38% from the stock’s current price.

Other equities analysts have also issued research reports about the company. TD Cowen dropped their price objective on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a report on Monday, May 4th. JPMorgan Chase & Co. decreased their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Argus dropped their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research report on Tuesday, April 14th. Finally, Barclays boosted their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus target price of $183.64.

Becton, Dickinson and Company Stock Down 0.5%

Shares of NYSE:BDX opened at $146.52 on Wednesday. The firm has a 50 day simple moving average of $152.11 and a 200-day simple moving average of $177.44. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $40.37 billion, a PE ratio of 36.96, a P/E/G ratio of 10.46 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. During the same quarter in the prior year, the business posted $3.35 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.

Institutional Trading of Becton, Dickinson and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Glenmede Trust Co. NA increased its holdings in shares of Becton, Dickinson and Company by 3.8% in the first quarter. Glenmede Trust Co. NA now owns 117,165 shares of the medical instruments supplier’s stock valued at $18,422,000 after purchasing an additional 4,342 shares during the period. Segall Bryant & Hamill LLC acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth $2,074,000. CTC Alternative Strategies Ltd. purchased a new position in Becton, Dickinson and Company in the 1st quarter valued at $393,000. Liontrust Investment Partners LLP increased its stake in Becton, Dickinson and Company by 18.0% in the 1st quarter. Liontrust Investment Partners LLP now owns 645,308 shares of the medical instruments supplier’s stock valued at $101,462,000 after buying an additional 98,212 shares during the period. Finally, Western Wealth Management LLC acquired a new position in Becton, Dickinson and Company in the 1st quarter valued at $41,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.